EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Clinical Spectrum and Outcomes of SOX1 Antibody‐Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Study

Jin-Long Ye iD, Zu-Ying Kuang, Bo Li, Meng-Qiu Pan, Li-Hua Zhou, Yang-Yang Dai, Si-Fen Xie, Xian-Guang Lin, Ye-Peng Hu, Li-Hong Jiang, Zhan-Hang Wang, Wei-Jing Zhang

Annals of Clinical and Translational Neurology · 2026-07 · 13 (7) · 1379-1387

DOI: 10.1002/acn3.70313 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 23.01.2026. Verfasst von Jin-Long Ye und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Guangdong Sanjiu Brain Hospital, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: SOXB1 Transcription Factors, Paraneoplastic Syndromes, Nervous System, Autoantibodies. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SOX1 antibody‐positive paraneoplastic neurological syndromes (PNS) exhibit significant population‐specific clinical heterogeneity. While Western cohorts predominantly manifest Lambert‐Eaton myasthenic syndrome (65%–80%), comprehensive clinical characterization and treatment response data in Asian populations remain critically limited.

Methods

We conducted a single‐center retrospective case series analyzing 13 consecutive patients with SOX1 antibody‐positive PNS treated at Guangdong Sanjiu Brain Hospital from January 2019 to December 2024. SOX1 antibodies were confirmed using commercial immunoblot assay. Primary endpoints included treatment response (≥ 1‐point improvement on modified Rankin Scale [mRS]) and functional recovery (mRS ≤ 2). Statistical analyses employed Fisher's exact tests and Mann–Whitney U tests.

Results

Among 13 patients (median age 61 years [IQR 56–67], 53.8% female), neuropsychiatric presentations predominated, including seizures (46.2%) and psychiatric symptoms (30.8%), with combined neuropsychiatric manifestations occurring in 53.8% of patients. Co‐existing neuronal antibodies were identified in 15.4% of cases (GABAB receptor, LGI1). Malignancy was confirmed in 30.8% of patients. Immunotherapy recipients ( n = 7) demonstrated significantly superior functional outcomes compared to non‐treated patients: median 3‐month mRS 0 (IQR 0–0) versus 3 (IQR 3–3), p = 0.03. Treatment response rates were 85.7% versus 33.3% ( p = 0.103).

Conclusions

Chinese patients with SOX1 antibody‐positive PNS demonstrate a neuropsychiatric‐predominant phenotype (53.8%), contrasting markedly with Western cohorts. Early immunotherapy administration was associated with superior functional outcomes (median 3‐month mRS: 0 vs. 3, p = 0.03). These findings support comprehensive neuronal antibody profiling and early immunotherapy consideration in patients presenting with neuropsychiatric manifestations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SOXB1 Transcription FactorsParaneoplastic Syndromes, Nervous SystemAutoantibodiesHumansFemaleMiddle AgedMaleRetrospective StudiesAgedChinaCohort StudiesEast Asian People

Stichwörter der Autor:innen

Chinese populationSOX1 antibodyclinical phenotypeimmunotherapyneuropsychiatric symptomsparaneoplastic neurological syndrometreatment response

Substanzen

SOXB1 Transcription FactorsSOX1 protein, humanAutoantibodies

Autor:innen und Institutionen

  • Department of Neurology, Guangdong Sanjiu Brain Hospital, Guangzhou, Guangdong, China.
  • Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical Uni…

ORCID-Profile: Jin-Long Ye

Zitieren

APA

Ye, J. L., Kuang, Z. Y., Li, B., Pan, M. Q., Zhou, L. H., Dai, Y. Y., Xie, S. F., Lin, X. G., Hu, Y. P., Jiang, L. H., Wang, Z. H., & Zhang, W. J. (2026). Clinical Spectrum and Outcomes of SOX1 Antibody‐Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Study. Annals of Clinical and Translational Neurology, 13(7), 1379-1387. https://doi.org/10.1002/acn3.70313

Vancouver

Ye JL, Kuang ZY, Li B, Pan MQ, Zhou LH, Dai YY, et al. Clinical Spectrum and Outcomes of SOX1 Antibody‐Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Study. Annals of Clinical and Translational Neurology. 2026;13(7):1379-1387. doi:10.1002/acn3.70313

BibTeX
@article{Ye2026,
  author = {Ye, Jin-Long and Kuang, Zu-Ying and Li, Bo and Pan, Meng-Qiu and Zhou, Li-Hua and Dai, Yang-Yang and Xie, Si-Fen and Lin, Xian-Guang and Hu, Ye-Peng and Jiang, Li-Hong and Wang, Zhan-Hang and Zhang, Wei-Jing},
  title = {Clinical Spectrum and Outcomes of SOX1 Antibody‐Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Study},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {7},
  pages = {1379--1387},
  doi = {10.1002/acn3.70313}
}
Kostenlos starten →